Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation

Human Immunology

Volumn 72, Issue 9, 2011, Pages 687-698

  Koay, Lok Beng ^a   Feng, I Che ^a   Sheu, Ming Jen ^a   Kuo, Hsing Tao ^a   Lin, Chin Yih ^a   Chen, Jyh Jou ^a   Wang, Shih Ling ^a   Tang, Ling Yu ^a   Tsai, Sun Lung ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Chronic hepatitis B; Gene profiling; HLA class II tetramer; Regulatory T cell clone; SYFPEITHI score

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; EPITOPE; HEPATITIS B CORE ANTIGEN; HLA ANTIGEN CLASS 2; LAMIVUDINE; TETRAMER; TRANSCRIPTION FACTOR FOXP3;

ANTIVIRAL THERAPY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE EXACERBATION; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; SCORING SYSTEM; UPREGULATION;

ANTIVIRAL AGENTS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSION; LIVER FAILURE; PROTEIN BINDING; REMISSION INDUCTION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84860389996     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.11.001     Document Type: Article

References (62)

1. Chen D.S. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993, 262:369-370.
2. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
3. Lok A.S.F. Chronic hepatitis B. N Engl J Med 2002, 346:1682-1683.
4. Morens D.M., Folkers G.K., Fauci A.S. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430:242-249.
5. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
6. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
7. Greenberg H.B., Pollard R.B., Lutwick L.I., Gregory P.B., Robinson W.S., Merigan T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976, 295:517-522.
8. Desmyter J., Ray M.B., De Groot J., Bradburne A.F., Desmet V.J., Edy V.G., et al. Administration of human fibroblast interferon in chronic hepatitis B infection. Lancet 1976, ii:645-647.
9. Hoofnagle J.H., DiBisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347-356.
10. Lok A.S.F., McMahon B.J. Chronic hepatitis B. Hepatol 2001, 34:1225-1241.
11. Sherman M., Shafran S., Burak K., Doucette K., Wong W., Girgrah N., et al. Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 2007, 5C-24C. 21;suppl C.
12. Papatheodoridis G.V., Manolakopoulos S., Dusheiko G., Archimandritis A.J. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008, 8:167-178.
13. Dienstag J.L. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
14. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003, 18:246-252.
15. Chien R.N., Lin C.L., Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003, 38:322-327.
16. Mashhour M.Y., Ghanaei F.M., Foroutan H., Ghofrani H., Purrasuli Z., Jourkar F. Efficacy of lamivudine therapy on decompensated liver cirrhosis due to chronic hepatitis B. Hep Mon 2007, 7:77-81.
17. Tuttleman J.S., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986, 47:451-460.
18. Yokosuka O., Omata M., Imazeki F., Ito Y., Okuda K. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986, 315:1187-1192.
19. Chotiyaputta W., Lok A.S.F. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009, 6:453-462.
20. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998, 339:114-115.
21. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 102:1009-1022.
22. Marinos G., Naoumov N.J., Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996, 24:991-995.
23. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998, 102:968-975.
24. Hultgren C., Weiland O., Milich D.R., Sallberg M. Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection. Clin Infect Dis 1999, 29:1575-1577.
25. Liaw Y.F., Tsai S.L., Chien R.N., Yeh C.T., Chu C.M. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000, 32:604-609.
26. Boni C., Penna A., Ogg G.S., Bertoletti A., Pilli M., Cavallo C., et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001, 33:963-971.
27. Tsai S.L., Sheen I.S., Chien R.N., Chu C.M., Chuang Y.L., Lee T.H., et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 2003, 10:120-135.
28. Lin C.L., Tsai S.L., Lee T.H., Chien R.N., Liao S.K., Liaw Y.F. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 2005, 54:152-161.
29. Tsai S.L., Chen P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H., et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992, 89:87-96.
30. Chu C.M., Liaw Y.F. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection: hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 1987, 2:220-226.
31. Tsai S.L., Chen M.H., Yeh C.T., Chu C.M., Lin A.N., Chiou F.H., et al. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J Clin Invest 1996, 97:577-584.
32. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunological self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causing various autoimmune diseases. J Immunol 1995, 155:1151-1164.
33. Kronenberg M., Rudenskym A.Y. Regulation of immunity by self-reactive T cells. Nature 2005, 435:598-604.
34. Belkaid Y., Rouse B. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-359.
35. Li S., Growans E.J., Chougnet C., Plebanski M., Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 2008, 82:21-30.
36. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J.W., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778.
37. Franzese O., Kennedy P.T.F., Gehring A.J., Gotto J., Williams R., Maini M.K., et al. Modulation of the CD8+ T cell response by CD4+ D25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005, 79:3322-3328.
38. Xu D., Fu J., Jin L., Zhang H., Zho C., Zou Z., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-747.
39. Cabrera R., Tu Z., Xu Y., Firpi R.J., Rosen H.R., Liu C., et al. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40:1062-1071.
40. Feng I.C., Koay L.B., Sheu M.J., Kuo H.T., Sun C.S., Lee C., et al. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J Biomed Sci 2007, 14:43-57.
41. Lee H.H., Uen Y.H., Tian Y.F., Sun C.S., Sheu M.J., Kuo H.T., et al. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev 2009, 18:1562-1569.
42. Chien R.N., Yeh C.T., Tsai S.L., Chu C.M., Liaw Y.F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003, 38:1267-1273.
43. Weaver C.T., Harrington L.E., Mangan P.R., Gavriell M., Murphy K.M.Th 17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
44. Steinman L. A brief history of T(H)17: the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007, 13:139-145.
45. Bettelli E., Korn T., Oukka M., Kuchroo V. Induction and effector function of T(H)17 cells. Nature 2008, 453:1051-1057.
46. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8:337-348.
47. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
48. Óshea J.J., Hunter C.A., Germain R.N. T cell heterogeneity: firmly fixed, predominantly plastic or merely malleable?. Nat Immunol 2008, 5:450-453.
49. Lee T.H., Huang C.Y.L., Tsai S.L., Liaw Y.F. Effects of lamivudine on the hepatitis B virusspecific CD8+ cytotoxic T lymphocyte response via peptide-MHC tetrameric complexesassay. Lett Pept Sci 2002, 8:179-185.
50. Rammensee H.G., Bachmann J., Emmerich N.N., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219. (Freeaccess viahttp://www.syfpeithi.de/).
51. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type-2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1977, 25:449-458.
52. Tsai S.L., Chen M.H., Huang C.Y., Chen Y.M., Sheen I.S., Yeh C.T., et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998, 115:954-966.
53. Nagler-Anderson C., Bhan A.K., Podolsky D.K., Terhorst C. Control freaks: immune regulatory cells. Nat Immunol 2005, 5:119-122.
54. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4+ T cells proliferating in response to influenza A antigen. J Clin Invest 1999, 104:R63-R66.
55. Novak E.J., Masewicz S.A., Liu A.W., Lernmark Å., Kwok W.W., Nepom G.T. Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset. Int Immunol 2001, 13:799-806.
56. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6:1219-1222.
57. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
58. Beasley R.P., Hwang L.Y. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983, 147:185-190.
59. Beasley R.P., Trepo C., Stevens C.E., Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105:94-98.
60. Milich D.R., Jones J.E., Hughes J.L., Price J., Raney A.K., McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?. Proc Natl Acad Sci U S A 1990, 87:6599-6603.
61. Ni Y.H., Chang M.H., Chen P.J., Tsai K.S., Hsu H.Y., Chen H.L., et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007, 132:2340-2345.
62. Milich D.R., McLachlan A., Raney A.K., Houghten R., Thornton G.B., Maruyama T., et al. Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proc Natl Acad Sci U S A 1991, 88:4348-4352.